全文获取类型
收费全文 | 3937篇 |
免费 | 292篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 171篇 |
妇产科学 | 122篇 |
基础医学 | 505篇 |
口腔科学 | 40篇 |
临床医学 | 760篇 |
内科学 | 701篇 |
皮肤病学 | 27篇 |
神经病学 | 323篇 |
特种医学 | 89篇 |
外科学 | 326篇 |
综合类 | 51篇 |
一般理论 | 3篇 |
预防医学 | 472篇 |
眼科学 | 49篇 |
药学 | 279篇 |
中国医学 | 9篇 |
肿瘤学 | 270篇 |
出版年
2022年 | 21篇 |
2021年 | 58篇 |
2020年 | 45篇 |
2019年 | 96篇 |
2018年 | 102篇 |
2017年 | 70篇 |
2016年 | 84篇 |
2015年 | 87篇 |
2014年 | 133篇 |
2013年 | 217篇 |
2012年 | 255篇 |
2011年 | 261篇 |
2010年 | 174篇 |
2009年 | 123篇 |
2008年 | 228篇 |
2007年 | 228篇 |
2006年 | 229篇 |
2005年 | 257篇 |
2004年 | 254篇 |
2003年 | 236篇 |
2002年 | 240篇 |
2001年 | 32篇 |
2000年 | 20篇 |
1999年 | 37篇 |
1998年 | 38篇 |
1997年 | 48篇 |
1996年 | 32篇 |
1995年 | 43篇 |
1994年 | 27篇 |
1993年 | 28篇 |
1992年 | 20篇 |
1991年 | 20篇 |
1990年 | 22篇 |
1989年 | 17篇 |
1988年 | 21篇 |
1986年 | 13篇 |
1985年 | 16篇 |
1984年 | 23篇 |
1983年 | 27篇 |
1982年 | 24篇 |
1981年 | 44篇 |
1980年 | 24篇 |
1978年 | 19篇 |
1977年 | 22篇 |
1976年 | 20篇 |
1975年 | 15篇 |
1974年 | 17篇 |
1973年 | 15篇 |
1972年 | 17篇 |
1967年 | 11篇 |
排序方式: 共有4231条查询结果,搜索用时 15 毫秒
1.
2.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
3.
Michael A. Gibney David Fitz-Patrick David C. Klonoff Shahista Whooley Betty Lu Wen Yue 《Current medical research and opinion》2020,36(10):1591-1600
Abstract
Objective
Two similarly designed studies compared user experiences with a second-generation extra-thin-wall, 5-bevel 32?G?×?4?mm pen needle (PN) with redesigned hub versus four thinner commercially available PNs. 相似文献4.
5.
Will Kaufman Augustine S Chavez Betty Skipper Arthur Kaufman 《International journal for equity in health》2006,5(1):6-5
Background
A public hospital in New Mexico required collection of 50% of estimated costs prior to elective surgeries for self-pay patients. This study assesses the impact of this policy on access to elective surgical procedures. 相似文献6.
Teenage pregnancy is a well-documented problem in the United States, with approximately 890,000 teenage pregnancies occurring each year. Although teen pregnancy rates have declined since 1991, rates remain higher than the mid-1970s and are fourfold those of European countries. Substantial morbidity and social problems result from these pregnancies, affecting the mother, her children, other family members, and society. Multiple educational approaches have been used, with few demonstrating significant reductions in teen pregnancy. School-based programs have been diverse and multifaceted. Recently, programs with a comprehensive approach have shown potential for success. In this article, characteristics and elements of promising school-based programs are identified and discussed. It is imperative that school nurses play an active role in developing and implementing prevention programs that incorporate rigorous evaluation. As health educators, school nurses are in a prime position to implement and evaluate the effectiveness of teen pregnancy prevention programs. 相似文献
7.
8.
9.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
10.